The FDA has approved budesonide oral suspension (Eohilia, Takeda) as the first oral treatment for eosinophilic esophagitis (EoE) in adults and children as young as 11 years. The medication will be available in single-dose stick packs and is designed to address esophageal inflammation and EoE dysphagia symptoms. The approval is based on efficacy and safety data from two 12-week studies, which showed significant improvement in histologic remission and reduction in dysphagia symptoms for patients receiving the active treatment compared to placebo. The most common adverse reactions include respiratory tract infection, gastrointestinal mucosal candidiasis, headache, and adrenal suppression. More information is available online.
Source link
FDA OKs First Oral Agent for Eosinophilic Esophagitis
